In short
PC14586, also known as rezatapopt, is an innovative oral medication currently being studied in clinical trials for its potential in treating various types of cancer. This article provides an overview of the ongoing research into PC14586, its mechanism of action, and its potential benefits for patients with specific genetic mutations in their cancer cells.
At a glance
- Drug Name
- PC14586 (rezatapopt)
- Drug Type
- First-in-class, oral, small molecule p53 reactivator
- Target
- TP53 Y220C mutation in solid tumors
- Cancer Types Studied
- Ovarian, lung, breast, endometrial, colorectal, prostate, head and neck cancers
- Clinical Trial Phases
- Phase 1/2
- Administration
- Oral capsules or tablets
- Key Objectives
- Safety, tolerability, pharmacokinetics, efficacy
- Combination Studies
- With pembrolizumab (immunotherapy)
- Efficacy Measures
- Overall Response Rate, Progression-Free Survival, Overall Survival
- Safety Monitoring
- Adverse events, vital signs, ECG, laboratory tests
What is PC14586?
PC14586, also known by its international nonproprietary name (INN) rezatapopt, is a new cancer drug currently being studied in clinical trials. It is described as a "first-in-class" medication, which means it works in a way that is different from other existing drugs. PC14586 is taken orally as a capsule or tablet.
How Does PC14586 Work?
PC14586 is designed to target a specific genetic mutation in cancer cells. It is called a "p53 reactivator" that is selective for the TP53 Y220C mutation. To understand this, let's break it down:
- p53: This is a protein in our body that helps prevent cancer by controlling cell growth and division. It's often called the "guardian of the genome."
- TP53: This is the gene that provides instructions for making the p53 protein.
- Y220C mutation: This is a specific change in the TP53 gene that can lead to cancer.
PC14586 is designed to "reactivate" or restore the normal function of p53 in cancer cells that have this specific Y220C mutation. By doing so, it aims to stop cancer cells from growing and dividing uncontrollably.
What Cancers Can PC14586 Treat?
PC14586 is being studied for the treatment of various types of advanced or metastatic solid tumors (cancers that form solid masses) that have the TP53 Y220C mutation. These include:
- Ovarian cancer
- Lung cancer
- Breast cancer
- Endometrial cancer (cancer of the lining of the uterus)
- Colorectal cancer
- Prostate cancer
- Head and neck cancer
- Other solid tumors
It's important to note that PC14586 is specifically designed for cancers with the TP53 Y220C mutation. This means that before a patient can receive this treatment, their cancer cells would need to be tested for this specific genetic change.
Current Research on PC14586
Several clinical trials are currently underway to study PC14586:
- Phase 1/2 Trial (PYNNACLE): This study is looking at the safety, how well the drug is tolerated, and how effective it is in patients with advanced solid tumors that have the TP53 Y220C mutation. It's testing PC14586 both alone and in combination with another cancer drug called pembrolizumab.
- Absorption, Metabolism, and Excretion Study: This study is examining how PC14586 is processed and eliminated by the body in healthy male volunteers.
- Food Effect Study: This research is investigating how food affects the way PC14586 is absorbed and processed by the body. It's also looking at how the drug behaves in Japanese volunteers.
- Drug Interaction Studies: These studies are examining how PC14586 interacts with other medications, specifically:
- Acid-reducing agents like rabeprazole and famotidine
- Itraconazole, an antifungal medication
These studies will help researchers understand how to best use PC14586, what dose to give, and what other medications might affect its effectiveness or safety.
Potential Side Effects
As PC14586 is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring for any adverse events (unwanted or harmful effects) that might occur. These could include:
- Changes in blood tests (hematology and clinical chemistry)
- Abnormalities in heart rhythm (detected by ECG)
- Changes in blood pressure
- Changes in pulse rate
- Changes in body temperature
It's important to remember that not all participants will experience side effects, and the benefits of the treatment may outweigh the risks for many patients.
Future Directions
The research on PC14586 is still in its early stages, but the results could potentially lead to a new targeted therapy for certain types of cancer. If successful, it could offer hope to patients whose cancers have the specific TP53 Y220C mutation.
Future research may explore: Combining PC14586 with other cancer treatments Using PC14586 in earlier stages of cancer Identifying other genetic mutations that PC14586 might be effective against
As with all new medications, it will take time and more research to fully understand the potential benefits and risks of PC14586. Patients interested in this treatment should discuss it with their oncologist to see if it might be appropriate for their specific situation.